No Data
No Data
Earnings Report: Byhealth Co., Ltd Missed Revenue Estimates By 29%
By-Health Co., Ltd. (300146.SZ): The VDS industry's glucosamine category achieved single-digit growth offline in the first half of the year, and over 20% growth online.
On August 7th, Gelonhui reported that By-Health Co., Ltd. (300146.SZ) recently held an investor relations event and responded to the question of whether the development of glucosamine category had reached a bottleneck. The company stated that in the first half of this year, the glucosamine category of VDS industry achieved single-digit growth offline and more than 20% growth online. The product strength of Jianliduo showed significant improvement after the new product switch.
By-Health Co., Ltd. (300146.SZ): The new product switch has put some pressure on the gross margin.
By-Health Co., Ltd. (300146.SZ) recently conducted an investor relations event. Regarding whether the iteration of new products will affect gross margin, the company responded that there is certain pressure on gross margin when switching to new products, and the increase in effective ingredient content of new products results in increased costs.
By-Health Co., Ltd. (300146.SZ): The performance of LSG's Australian domestic market in the first half of the year was basically flat compared to the same period last year, with a slight decline in cross-border revenue.
By-Health Co., Ltd. (300146.SZ) recently held an investor relations activity regarding the performance of LSG in Australia, and responded that in the first half of this year, the performance in the local market of LSG was basically flat compared to the same period last year, and the cross-border revenue slightly declined.
By-Health Co., Ltd. (300146.SZ): There is not much difference in the proportion of interest e-commerce revenue compared to the same period last year.
On August 7th, Gelonhui reported that By-Health Co., Ltd. (Stock code: 300146.SZ) recently held an investor relations event. In response to the question regarding the proportion of interest-based e-commerce revenue in the first half of the year, the company replied that the proportion did not change significantly compared to the same period last year.
By-Health Co., Ltd. (300146.SZ): The full-year sales expense ratio is expected to be controlled within 45%.
On August 7th, Gelunhui reported that By-Health Co., Ltd. (300146.SZ) conducted investor relations activities recently. Regarding the 'estimated expense ratio for the year', the company replied that the sales expense conversion in the first half of the year did not reach expectations. The company will actively adjust the expense input model in the second half of the year and hope to control the annual sales expense ratio within 45%. However, there is a certain uncertainty in the effects of relevant adjustments under the continuous rapid changes in the online environment.
No Data